CMS advises Almirall on acquisition of respiratory disease business by AstraZeneca
Pharmaceutical firm Almirall has agreed with London-based AstraZeneca to transfer its drug platform for respiratory disease treatments. Once the transaction is completed, AstraZeneca will pay USD 875 million for the rights. Up to USD1.22 billion is additionally payable if certain milestones are reached with regard to the development, launch